NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026
I'm PortAI, I can summarize articles.
NeuroSense Therapeutics has completed data collection for its Phase 2 clinical trial of PrimeC in Alzheimer's disease, known as the RoAD study. The database is locked, and all clinical data from eight patients are finalized for analysis. Topline results are expected in Q1 2026, with further details to be discussed in a webinar on December 8. This update is informational and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments